Authors' Reply to Gandjour: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation"

Monika Wagner¹, Mireille Goetghebeur^{2

3}

Affiliations

¹ LASER Analytica, 3100 Côte-Vertu Boulevard, Suite 230, St-Laurent, QC, H4R 2J8, Canada. monika.wagner@la-ser.com.
² LASER Analytica, 3100 Côte-Vertu Boulevard, Suite 230, St-Laurent, QC, H4R 2J8, Canada.
³ School of Public Health, University of Montreal, Montreal, QC, Canada.

Comment

Monika Wagner et al. Pharmacoeconomics. 2017 May.

. 2017 May;35(5):605-606.

doi: 10.1007/s40273-017-0498-0.

Monika Wagner¹, Mireille Goetghebeur^{2

3}

¹ LASER Analytica, 3100 Côte-Vertu Boulevard, Suite 230, St-Laurent, QC, H4R 2J8, Canada. monika.wagner@la-ser.com.
² LASER Analytica, 3100 Côte-Vertu Boulevard, Suite 230, St-Laurent, QC, H4R 2J8, Canada.
³ School of Public Health, University of Montreal, Montreal, QC, Canada.

No abstract available

Comment on

Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.
Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. Wagner M, et al. Pharmacoeconomics. 2016 Mar;34(3):285-301. doi: 10.1007/s40273-015-0340-5. Pharmacoeconomics. 2016. PMID: 26547306 Free PMC article.
Comment on: "Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation".
Gandjour A. Gandjour A. Pharmacoeconomics. 2017 May;35(5):603-604. doi: 10.1007/s40273-017-0493-5. Pharmacoeconomics. 2017. PMID: 28324438 No abstract available.